Effect of amantadine in essential tremor: A randomized, placebo‐controlled trial
Identifieur interne : 003466 ( Main/Exploration ); précédent : 003465; suivant : 003467Effect of amantadine in essential tremor: A randomized, placebo‐controlled trial
Auteurs : Alexandre Gironell [Espagne] ; Jaime Kulisevsky [Espagne] ; Berta Pascual-Sedano [Espagne] ; David Flamarich [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-04.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Accelerometry, Aged, Amantadine, Amantadine (therapeutic use), Antiparkinson Agents (therapeutic use), Cross-Over Studies, Disability Evaluation, Double-Blind Method, Essential Tremor (drug therapy), Female, Humans, Male, Middle Aged, Motor Activity (drug effects), Nervous system diseases, Neurophysiology, Placebo, Treatment Outcome, Tremor, accelerometry, amantadine, essential tremor.
- MESH :
- chemical , therapeutic use : Amantadine, Antiparkinson Agents.
- drug effects : Motor Activity.
- drug therapy : Essential Tremor.
- Aged, Cross-Over Studies, Disability Evaluation, Double-Blind Method, Female, Humans, Male, Middle Aged, Neurophysiology, Treatment Outcome.
Abstract
There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double‐blind, cross‐over, placebo‐controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1‐week wash‐out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self‐reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two‐way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20676
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002879
- to stream Istex, to step Curation: 002879
- to stream Istex, to step Checkpoint: 001F26
- to stream PubMed, to step Corpus: 002E26
- to stream PubMed, to step Curation: 002E26
- to stream PubMed, to step Checkpoint: 002D57
- to stream Ncbi, to step Merge: 001503
- to stream Ncbi, to step Curation: 001503
- to stream Ncbi, to step Checkpoint: 001503
- to stream Main, to step Merge: 004780
- to stream PascalFrancis, to step Corpus: 001B86
- to stream PascalFrancis, to step Curation: 001135
- to stream PascalFrancis, to step Checkpoint: 001B27
- to stream Main, to step Merge: 004C22
- to stream Main, to step Curation: 003466
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of amantadine in essential tremor: A randomized, placebo‐controlled trial</title><author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name></author><author><name sortKey="Pascual Edano, Berta" sort="Pascual Edano, Berta" uniqKey="Pascual Edano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name></author><author><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AE16BD46D1ADDC8FFF0A061FA693BE9E4205F2EB</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20676</idno><idno type="url">https://api.istex.fr/document/AE16BD46D1ADDC8FFF0A061FA693BE9E4205F2EB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002879</idno><idno type="wicri:Area/Istex/Curation">002879</idno><idno type="wicri:Area/Istex/Checkpoint">001F26</idno><idno type="wicri:doubleKey">0885-3185:2006:Gironell A:effect:of:amantadine</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16229019</idno><idno type="wicri:Area/PubMed/Corpus">002E26</idno><idno type="wicri:Area/PubMed/Curation">002E26</idno><idno type="wicri:Area/PubMed/Checkpoint">002D57</idno><idno type="wicri:Area/Ncbi/Merge">001503</idno><idno type="wicri:Area/Ncbi/Curation">001503</idno><idno type="wicri:Area/Ncbi/Checkpoint">001503</idno><idno type="wicri:doubleKey">0885-3185:2006:Gironell A:effect:of:amantadine</idno><idno type="wicri:Area/Main/Merge">004780</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0244403</idno><idno type="wicri:Area/PascalFrancis/Corpus">001B86</idno><idno type="wicri:Area/PascalFrancis/Curation">001135</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B27</idno><idno type="wicri:doubleKey">0885-3185:2006:Gironell A:effect:of:amantadine</idno><idno type="wicri:Area/Main/Merge">004C22</idno><idno type="wicri:Area/Main/Curation">003466</idno><idno type="wicri:Area/Main/Exploration">003466</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of amantadine in essential tremor: A randomized, placebo‐controlled trial</title><author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Pascual Edano, Berta" sort="Pascual Edano, Berta" uniqKey="Pascual Edano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04">2006-04</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="441">441</biblScope><biblScope unit="page" to="445">445</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AE16BD46D1ADDC8FFF0A061FA693BE9E4205F2EB</idno><idno type="DOI">10.1002/mds.20676</idno><idno type="ArticleID">MDS20676</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accelerometry</term><term>Aged</term><term>Amantadine</term><term>Amantadine (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Essential Tremor (drug therapy)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Nervous system diseases</term><term>Neurophysiology</term><term>Placebo</term><term>Treatment Outcome</term><term>Tremor</term><term>accelerometry</term><term>amantadine</term><term>essential tremor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Over Studies</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurophysiology</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Accélérométrie</term><term>Amantadine</term><term>Placebo</term><term>Système nerveux pathologie</term><term>Tremblement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double‐blind, cross‐over, placebo‐controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1‐week wash‐out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self‐reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two‐way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name></noRegion><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><name sortKey="Pascual Edano, Berta" sort="Pascual Edano, Berta" uniqKey="Pascual Edano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003466 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003466 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AE16BD46D1ADDC8FFF0A061FA693BE9E4205F2EB
|texte= Effect of amantadine in essential tremor: A randomized, placebo‐controlled trial
}}
| This area was generated with Dilib version V0.6.23. |  |